Jinan Jiage Biological Technology Co, Ltd

Jinan Jiage Biological Technology Co, Ltd

You are here: HomeProductsEvista (Raloxifene Hydrochloride)

Contact us

  • Company Name: Jinan Jiage Biological Technology Co, Ltd
  • Street: No 28, Sankongqiao Road, Tianqiao District, Jinan
  • City: Jinan
  • Province/state: Shandong
  • Country/region: China
  • Contact Person: Ms.Lillian Cao
  • Department: Sales
  • Tel: 86-0531-15564141272
  • Fax: 86-0531-85826061
  • Email:
  • Chat with supplier using
    yc2016

Evista (Raloxifene Hydrochloride)

  • CAS No:82640-04-8 [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-<br />ylethoxy)phenyl]methanone
    Molecular Structure

    Detailed Description

    Evista (Raloxifene Hydrochloride)
    CAS No.: 82640-04-8
    Purity: 99%
    Molecular Formula: C28H29NO4S
    Molecular Weight: 475.5992
    Apperance: White powder
    Specification: USP
    Uses: For osteoporosis prevention of postmenopausal women
    Packing: 1kg/aluminum foil bag
    Min. Order quantity: 10g
    Descritpion:
    Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen
    receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological
    actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results
    in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic
    pathways in other tissues (Antagonism).
    Application:
    May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
    Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
    Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
    Packing:
    Discreet packing ways as your requirement, 100% go through.
    Storage:
    Store in cool and dry area and keep away from direct sunlight.
    Advantage:
    1. Rich experience.
    Our company is a professional production leading factory in China in pharmaceutical area of many years, our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, we had Established long friendly relations of cooperation.
    2. Great quality, purity and favourable.
    Good quality is one of our secret success, welcome order the samples, MOQ just 10 grams.
    3. Safe and fast delivery.
    We have stock, so we can delivery quickly at the very day when receive the payment.
    We have special way could ship 0.01kg to 3.5kg products a time. We offer melting powder into liquid service. And ship the liquid in special bottles.
    4. Good after-sales service.
  • Evista (Raloxifene Hydrochloride)
  • Evista (Raloxifene Hydrochloride)